已收盘 05-15 16:00:00 美东时间
-0.740
-3.31%
Goldman Sachs analyst Caitlin Burrows maintains Macerich (NYSE:MAC) with a Sell and raises the price target from $17 to $19.
05-15 23:44
今日重点评级关注:瑞杰金融:上调InflaRx评级至"强烈买入",目标价从7美元升至9美元;巴克莱:维持Orchestra BioMed Hldgs"超配"评级,目标价从12美元升至13美元
05-14 14:32
BRIEF-Macerich Announces Pricing Of Upsized Public Offering Of Common Stock May 11 (Reuters) - Macerich Co MAC.N : MACERICH ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING OF COMMON STOCK MACERICH CO - PRICES 19.2 MILLION SHARE OFFERING AT $21.00 PER SHARE FOR $403.2 MILLION GROSS PROCEEDS Source text:
05-12 08:50
Macerich prices upsized 19,200,000-share offering at $21 per share Macerich priced an upsized underwritten public offering of 19,200,000 common shares at USD 21 per share, implying gross proceeds of about USD 403.2 million. Underwriters received a 30-day option to buy up to 2,880,000 additional shar
05-12 08:49
Macerich prices upsized 19,200,000-share follow-on offering at $21 per share Macerich priced upsized underwritten follow-on offering of 19,200,000 common shares at USD 21 per share, targeting gross proceeds of about USD 403.2 million. Underwriters received 30-day option to buy up to 2,880,000 additi
05-12 08:48
The Macerich Company (NYSE: MAC) (the "Company" or "Macerich") announced today that it has commenced an underwritten public offering of 16,000,000 shares of common stock. The Company expects to grant the underwriters a
05-12 04:33
The Macerich Company (NYSE: MAC) on Monday said it launched an underwritten public offering of 16 million shares of common stock. The shopping mall operator said it expects to grant underwriters a 30-...
05-12 04:29
Macerich Company announced an underwritten public offering of 19.2 million shares at $21.00 per share, raising approximately $403.2 million. The company also granted underwriters a 30-day option to purchase up to an additional 2.88 million shares. Proceeds will be used to repay borrowings related to Annapolis Mall acquisition and for general corporate purposes, including property acquisitions and strategic investments. Goldman Sachs is the lead b...
05-12 00:47
今日重点评级关注:HC Wainwright & Co.:维持Artiva Biotherapeutics"买入"评级,目标价从15美元升至35美元;韦德布什:维持Cullinan Therapeutics"跑赢大市"评级,目标价从36美元升至37美元
05-11 15:43
Evercore ISI Group analyst Samir Khanal maintains Macerich (NYSE:MAC) with a In-Line and raises the price target from $21 to $22.
05-08 21:52